Latest news

A $200,000 grant from MSWA will support research into proteins linked to the progression of motor neurone disease (MND) as well as a ground-breaking national study into the needs of carers and families of people experiencing end-of-life care and bereavement.

Read more

Foresight is a gift worth treasuring because it allows one to know what the future might hold. Andrew Francis often circles this concept when thinking about how different his life could be. From a young age, he knew about a hereditary gene that might, or might not affect his life, and future generations. It wasn’t until 2002 that Andrew got his answer.

Read more

The U.S. Food and Drug Administration (FDA) has issued a warning about the MS medication Lemtrada® (alemtuzumab).

Jessica Allen, an Australian professional cyclist, spends half of the year living in Italy, racing in the Union Cycliste Internationale World Tour across Europe, and the other half competing in Australia. She knows all about what it takes to be a successful cyclist and hopes to win gold for Australia at the next Olympic Games. However, amongst her busy schedule, Jessica always finds time to ride in the annual MSWA Ocean Ride - Powered by Retravision.

Lisa MacLennan was 41 and in the prime of her life. She was married with two young children, working in the disability sector, and two units away from completing a Bachelor of Social Work, when she was struck down by a severe stroke in 2012.

Winner, winner, chicken dinner was Nicolette Murphy’s initial response after recently attending an NDIS information session organised by MSWA at the Clarkson Library. The 48-year old who was diagnosed with multiple sclerosis in 2010 said the session with MSWA’s NDIS experts was more than she’d expected.

As the National Disability Scheme (NDIS) continues to roll-out across Perth and the South West, MSWA is holding an open day at its centre in Wilson to help people with their NDIS plans and showcase its latest renovations and upgrades.

MAVENCLAD® (cladribine tablets) has been recommended for listing on the Pharmaceutical Benefits Scheme (PBS) for relapsing remitting MS (RRMS), by the Pharmaceutical Benefits Advisory Committee (PBAC), subject to final approval by the Federal Health Minister.

For the thousands of Western Australians living with multiple sclerosis (MS) new treatments offer hope and relief. But for clinicians it’s often challenging to know if a particular treatment is working.